Clinical Study on Thalidomide Combined with Prednisone in the Treatment of Patients with Severe Ulcerative Colitis
Objective To explore the clinical effect of thalidomide combined with prednisone in the treatment of patients with severe ulcerative colitis(UC).Methods A total of 120 patients with severe UC admitted to our hospital from January 2021 to December 2022 were selected and randomly divided into two groups,with 60 cases in each group.The reference group was treated with prednisone,and the study group was treated with thalidomide on the basis of the reference group.The therapeutic effect,inflammatory factor levels and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the study group was 83.33％,significantly higher than 58.33％in the reference group(P＜0.05).After treatment,the levels of serum IL-2 and IFN-y in the study group were significantly lower than those in the reference group,and the levels of IL-4 and IL-10 were significantly higher than those in the reference group(P＜0.05).No significant difference was found in the total incidence of adverse reactions between the study group and the reference group(15.00％vs.13.33％,P＞0.05).Conclusions Thalidomide combined with prednisone in the treatment of severe UC has significant effect and high safety,which can obviously relieve patients'inflammatory reaction.
Severe ulcerative colitisThalidomidePrednisoneTherapeutic effectInflammatory factorAdverse reaction
国家科技期刊平台
NSTL
万方数据
